Loading…
← CockpitCompetitor Analysis › SANA Sana Biotechnology, Inc.Open in the cockpit ↗

Sana Biotechnology, Inc.SANACompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum laggard 9
Mkt cap
$554M
US dollars, full cap
Free float
62%
of shares outstanding
$/day
$6.26M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-143.9 pp
WACC 15.6%
Hurdle
n/a
no reverse DCF
Next earnings
125 days
23 Mar 2027
Close · USD$1.85
1D-1.6%
1W-19.2%
1M-21.6%
3M-50.5%
6M-40.5%
YTD-54.5%
1Y-49.2%
ATR %9.7%
Beta2.20
52w lowhigh66.3% off high

What Sana Biotechnology does

Employees: 142

Sana Biotechnology at a glance

Size Sana Biotechnology (SANA) is a United States Health Care company (Biotechnology) with a market value of $554M, the 2597th largest of 3,085 United States companies the cockpit tracks. Shares closed at $1.85 on 18 Nov 2026.

Performance Over six months the shares fell 40.5%, against -13.8% for the median peer and -2.2% for the United States market (cap-weighted) — 4th lowest of 19 in its peer set.

Capital Return on invested capital runs 143.9 points below its cost of capital (15.6% WACC).

Short interest Short interest is 13.6% of the free float (30 Oct 2026).

Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).

Relative performance

7510012521 May 202621 Aug 202618 Nov 2026Peer median 86SANA 59
Six months, rebased to 100: Sana Biotechnology against the median of its 20 peers (local-currency closes).

Sana Biotechnology financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$10.6M-$12.8M-$15.5M-$30.9M-$27.7M
EBITDA-$166M-$178M-$256M-$295M-$241M
Net income-$149M-$244M-$267M-$283M-$269M
Free cash flow-$145M-$145M-$257M-$274M-$311M
Capital expenditure$3.57M$938,000$33.4M$20.0M$20.9M
Total debt$53.8M$78.9M$94.2M$104M$108M

Quarterly statements and history in the cockpit →

Sana Biotechnology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%0%+50%+100%300871300404WVECLYM1521GNFT1672FDMT300318688639SRZN6586SANA6-month return →1-month return →
Up and to the right = strong over both horizons. Sana Biotechnology is the large dot.

Sana Biotechnology competitors and peer comparison

How Sana Biotechnology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sana Biotechnology against its 20 peers (data as of 18 Nov 2026)
MeasureSANAPeer medianRank in peer set
1-month return-21.6%-14.3%4th lowest of 21
6-month return-40.5%-13.8%4th lowest of 19
Distance from 52-week high-66.3%-45.5%4th lowest of 21
ROIC minus cost of capital-143.9 pp-3.4 pplowest of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Sana Biotechnology SANAUnited States$554M-41%n/an/an/an/an/a
Hvsen Biotechnology 300871.SZChina$553M-22%+2%17%2.3×n/an/a
Boji Medical Technology 300404.SZChina$561M-6%+32%4%3.4×31.9%+27.2%
Wave Life Sciences WVEUnited States$546M-55%-35%-321%2.2×n/an/a
Climb Bio CLYMUnited States$546M-12%n/an/an/an/an/a
Frontage 1521.HKHong Kong$542M+113%+10%8%2.3×14.3%+15.4%
Genfit GNFT.PAFrance$571M+22%+28%-130%11.0×39.8%+143.5%
Ascletis Pharma 1672.HKHong Kong$571M-72%-59%-71,976%1,794.8×n/an/a
4D Molecular Therapeutics FDMTUnited States$578M+23%+79,952%-226%3.2×n/an/a
Beijing Bohui Innovation Biotechnology 300318.SZChina$518M-20%-1%-13%6.2×n/an/a
Alebund Pharmaceuticals (Jiangsu) 9637.HKHong Kong$595Mn/a+674%-495%26.8×n/an/a
LongBio Pharma (Suzhou) 1779.HKHong Kong$510Mn/an/an/an/an/an/a
Anhui Huaheng Biotechnology 688639.SSChina$605M-45%+7%3%1.9×n/an/a
Surrozen SRZNUnited States$605M+17%+192%-485%48.5×n/an/a
Valneva VLA.PAFrance$508M-6%-27%-87%3.9×n/an/a
Design Therapeutics DSGNUnited States$606M-15%n/an/an/an/an/a
Beijing Scitop Bio-Tech 300858.SZChina$501M-28%+4%8%7.5×n/an/a
Sinotherapeutics 688247.SSChina$494M-19%-17%0%6.2×29.4%+7.0%
Getein Biotech 603387.SSChina$625M-13%+8%21%2.6×-8.9%-1.3%
Liaoning Dingjide Petrochemical 603255.SSChina$490M-24%+70%5%5.2×n/an/a
CHO Pharma 6586.TWOTaiwan$488M+24%-47%-17,694%8,281.1×n/an/a

Questions

Which companies are Sana Biotechnology's closest peers?
The cockpit's peer set: Hvsen Biotechnology (300871.SZ), Boji Medical Technology (300404.SZ), Wave Life Sciences (WVE), Climb Bio (CLYM), Frontage (1521.HK), Genfit (GNFT.PA), Ascletis Pharma (1672.HK), 4D Molecular Therapeutics (FDMT).
How has Sana Biotechnology stock performed?
Over six months to 18 Nov 2026 the shares returned -40.5% against -13.8% for the median peer; over one year -49.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.